TARLATAMAB

The PBAC recommended tarlatamab for the treatment of extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after first line treatment with platinum-based chemotherapy. The PBAC recalled the input it received from healthcare professionals and individuals prior to its March 2026 meeting, and welcomed additional input provided for this resubmission from a health care professional and an individual. The PBAC noted that there was currently a high clinical need for effective therapies for ES-SCLC, noting that patients currently have few effective treatment options, with only modest clinical benefit, and typically face rapidly progressive disease, substantial symptom burden, and short survival.
 
While the resubmission (using the early resolution pathway) addressed the outstanding issues related to the restriction criteria and financial estimates, the PBAC noted it did not implement the requested changes to the economic model requested in March 2026. The PBAC considered that a substantial price reduction was required to achieve a cost-effective listing and a risk sharing arrangement was required to mitigate the risk that people would access the subsidy outside the proposed criteria.